“Do We Want Science to Reinvent Human Aging?”
By Bill McKibben and Gregory Stock,
Transcript of live debate
| 03. 27. 2003
Daniel Perry, Executive Director, Alliance for Aging Research:
Good afternoon, my name is Dan Perry and I’m the Executive
Director of the not-for-profit Alliance for Aging Research.
It gives me great pleasure to welcome you to the second debate
under the banner of SAGE Crossroads. This is a project that
will continue for the next three years, bringing to light the
crosscurrents in our political life that affect the science
of aging. We know that there is a great deal of research going
on in the United States and around the world trying to plum
the secrets of human aging, and as it increasingly becomes possible
to modify the trajectory of human aging there will certainly
be consequences, indeed controversies, that go to our economics,
our politics, our religion and our sense of ourselves as human
beings.
Today’s debate is one that really brings focus very sharply
on this question, as we will soon hear from our two esteemed
participants, Doctor Gregory Stock, who is the director of UCLA’s
Program on Medicine, Technology and Society, and a widely quoted
lecturer...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...